86938-17-2

Usage

Uses

Used in Medicinal Chemistry:
BOC-GLU-OET DCHA is used as a coupling reagent in the synthesis of peptides, facilitating the formation of peptide bonds. Its structure allows for selective deprotection and subsequent modification of specific amino acid residues within a peptide sequence, which is essential for the development of peptide-based pharmaceuticals.
Used in Drug Development:
In the field of drug development, BOC-GLU-OET DCHA is utilized for the production of peptide-based pharmaceuticals. Its ability to facilitate the formation of peptide bonds and enable selective modification of amino acid residues contributes to the creation of novel and effective therapeutic agents.
Used in Solid-Phase Peptide Synthesis:
BOC-GLU-OET DCHA is employed in solid-phase peptide synthesis, a technique that allows for the stepwise assembly of peptides in a controlled and efficient manner. This method is widely used in the synthesis of complex peptide sequences and is crucial for the development of new drugs and therapeutic agents.

Upstream product

• 64-17-5 ethanol 
• 2419-94-5 Boc-Glu 
• 52454-78-1 L-glutamic acid α-ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 141-78-6 ethyl acetate 
• 13574-13-5 Boc-Glu(OBzl)-OH 
• 83173-71-1 2-(S)-tert-butoxycarbonylaminopentanedioic acid 5-benzyl ester 1-ethyl ester 

Downstream Products

• 1221686-75-4 (S)-2-tert-butoxycarbonylamino-4-(3-{3-[4-(pyridin-2-yloxymethyl)-benzyl]-isoxazol-5-yl}-pyridin-2-ylcarbamoyl)-butyric acid ethyl ester 
• 1336933-34-6 3-[(4S)-4-amino-5-ethoxy-5-oxopentanamido]-5-chloro-2-hydroxybenzene-1-sulfonic acid 
• 1336933-77-7 C₁₈H₂₅ClN₂O₉S 
• 1948-29-4 (S)-2-Amino-4-(carboxymethyl-carbamoyl)-butyric acid 
• 7432-24-8 L-g-Glutamyl-L-phenylalanine 
• 2566-39-4 (S)-2-((S)-4-Amino-4-carboxy-butyrylamino)-4-methyl-pentanoic acid 
• 1116-22-9 γ-L-glutamyl-L-glutamic acid 
• 1116-22-9 (S)-2-((R)-4-amino-4-carboxybutanamido)pentanedioic acid 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 

Relevant academic research and scientific papers

PRODUCTION PROCESSES OF S- AND O-DIACYLATED GAMMA-GLUTAMYL-CYSTEAMINE PRODRUGS

Methods are provided for the synthesis of a compound of formula (X). R2 is selected from -H, -C1-C4-alkyl,-C2-C4-alkenyl and C1-C4-aryl; R3 is selected from -C(O)H and

Preparation method of (s)-1-(t-butyloxycarboryl)-5-oxopyrrolidine-2-carboxylic acid ethyl ester

The invention discloses a preparation method of (s)-1-(t-butyloxycarboryl)-5-oxopyrrolidine-2-carboxylic acid ethyl ester and aims at mainly solving the technical problems of complexity, long period,high cost, low yield and the like in the original technology. In the technical scheme of the invention, the preparation method comprises the following steps of step 1, preparation of boc-glu-oet: mixing h-glu-oet with a protective agent of boc- groups to prepare the boc-glu-oet, or mixing boc-glu-oh with ethyl acetate, performing reaction on a mixture under the action of diazoalkane, and performing treatment to obtain the boc-glu-oet; step 2, preparation of carboxyl active ester of the boc-glu-oet: mixing the boc-glu-oet with a carboxyl activating reagent, and performing low-temperature reaction on a mixture under the action of condensing agent to prepare a carboxyl activator of the boc-glu-oet; and sep 3, preparation of boc-pyr-oet: performing intramolecular cyclization on the carboxyl activator of the boc-glu-oet to prepare a crude product, and then performing extraction, purification and crystallization to obtain a target product. The preparation method provided by the invention greatly simplifies the process route, lowers the cost and is suitable for mass production.

Synthesis of diacylated γ3-glutamyl-cysteamine prodrugs, and in vitro evaluation of their cytotoxicity and intracellular delivery of cysteamine

To overcome the major disadvantages of cysteamine, the only registered treatment for the rare genetic disease cystinosis, nine prodrugs of γ3-glutamyl-cysteamine (4) were synthesized for evaluation. Esterification of the thiol conferred oxidative stabilit

A pemetrexed quality control method and pemetrexed impurity and its salt preparation

The invention provides a pemetrexed quality control method, and preparation of a pemetrexed impurity and salt thereof. The pemetrexed impurity is synthesized from the raw material N-tert-butoxycarbonyl-L-glutamic acid-5-benzyl ester. The pemetrexed qualit

PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY

A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.

GLUTAMATE DERIVATIVES OR SALTS THEREOF

Compounds having an excellent CaSR agonist activity are in demand. The invention provides glutamate derivatives or salts thereof, pharmaceutical compositions comprising the glutamate derivatives, preventive or therapeutic agents for diarrhea, hyperparathyroidism or peptic ulcer.

PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME

The present invention provides an antifungal agent which has excellent antifungal action, and which is also excellent in terms of its properties, and in particular its solubility in water and safety. The present invention discloses a compound represented

Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-π-specific inhibitor O 1-hexadecyl-γ-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester

Cholangiocarcinoma is markedly resistant to chemotherapy and has a dismal prognosis, but its mechanism of drug resistance is unknown. This study examines whether glutathione S-transferase-π (GSTP1-1) is involved in resistance to anticancer drugs in cholangiocarcinoma and whether GSTP1-1-specific inhibitors can overcome this resistance. First, immunohistochemical examination disclosed strong staining of all our 17 cholangiocarcinoma specimens for GSTP1-1, irrespective of histological type. Transfection of the GSTP1-1 antisense expression vector into a human cholangiocarcinoma cell line (HuCCT1) apparently decreased its intracellular GSTP1-1 concentration, and the sensitivity of transfectants to adriamycin (ADR), cisplatin, and alkylating agents such as melphalan and 4-hydroxyperoxycyclophosphamide (4-HC) was increased significantly, compared with that of mock transfectants. We next synthesized GSTP1-1-specific inhibitors by elongating the carbon chain of the ethylester at the N-terminal of γ-glutamyl-S-benzylcysteinyl-phenylglycyl diethylester and performed a pharmacokinetic study on them. Of six GSTP1-1 inhibitors tested, O1-hexadecyl-γ-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester (C16C2) showed the smallest volume of central compartment and smallest volume of distribution at steady state and the second smallest clearance, being the most effective inhibitor in vivo. The IC50 value of ADR or 4-HC for HuCCT1 cells decreased greater by treatment with C16C2 in a dose-dependent manner, paralleling the decrease in GSTP1-1 activity, than that of ADR or 4-HC alone. The antitumor activity of ADR or cyclophosphamide was clearly enhanced by combination therapy with C16C2 in a xenograft model. In conclusion, our results demonstrated that GSTP1-1 is a resistance factor for anticancer drugs in cholangiocarcinoma and that C16C2, a GSTP1-1-specific inhibitor, is a potent agent against the resistance.

SYNTHESIS OF AMINO ACID ESTERS BY PAPAIN

A wide range of N-Boc-amino acid esters were synthesized from N-Boc-amino acids and alcohol using papain as catalyst.Suitable biphasic reaction mixtures were found for most amino acids to achieve high yield of ester synthesis.With N-Boc-L-aspartic and glutamic acids only the α carbonyl group esterified, without racemisation.